Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848663 · ClinicalTrials.gov registry record · NA
Visual Remapping to Aid Reading With Field Loss
A NA study of Age-related Macular Degeneration, sponsored by University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT03848663: Recruiting NA study of Age-related Macular Degeneration, sponsored by University of Minnesota.
NCT03848663 is a NA study of Age-related Macular Degeneration that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 108 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03848663, a NA study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
Primary Outcome
How quickly participants can correctly read displayed text
Conditions Studied
Interventions
- BEHAVIORAL Traditional Remapping
- BEHAVIORAL Personalized Remapping
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
What NCT03848663 shows while recruiting
NCT03848663 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Traditional Remapping is the first listed.
NCT03848663 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03848663 about?
NCT03848663 is a clinical study titled "Visual Remapping to Aid Reading With Field Loss". Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
What is the current status of trial NCT03848663?
This trial is currently recruiting. It is a NA study. The enrollment target is 108 participants. The study started on 2022-02-01. Estimated completion is 2026-07-01.
What conditions does trial NCT03848663 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT03848663?
The interventions under investigation include: Traditional Remapping (BEHAVIORAL), Personalized Remapping (BEHAVIORAL).
Who is sponsoring clinical trial NCT03848663?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03848663 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03848663's enrollment target sits among peer trials
108 30th of 74 higher than 45 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
-
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT04229043 · 108 participants · NA
Gastric Emptying of Water and Sports Drink in Labor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI